FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Zalutsky

Research Profile

Chemicals & Drugs

Living Beings

Concepts & Ideas

Tissue Distribution

Disorders

Procedures

Anatomy

Objects

Alpha Particles

Co-author Network

Publications

TOP 3
Marek Pruszynski; Hilde Revets; Ganesan Vaidyanathan; Nick Devoogdt; Eftychia Koumarianou; Tony Lahoutte; Michael R Zalutsky
Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.
Ganesan Vaidyanathan; P C Welsh; B J White; Donna J Affleck; J Choi; D McDougald; Xiao-Guang Zhao; Michael R Zalutsky
SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies.
Satish K Chitneni; Mark W Dewhirst; Gerald T Bida; Michael R Zalutsky
A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5).

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Zalutsky (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Marek Pruszynski; Hilde Revets; Ganesan Vaidyanathan; Nick Devoogdt; Eftychia Koumarianou; Tony Lahoutte; Michael R Zalutsky
Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.
Nuclear medicine and biology 2013;40(1):52-9.
2012: Ganesan Vaidyanathan; P C Welsh; B J White; Donna J Affleck; J Choi; D McDougald; Xiao-Guang Zhao; Michael R Zalutsky
SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies.
Bioorganic & medicinal chemistry 2012;20(24):6929-39.
2012: Satish K Chitneni; Mark W Dewhirst; Gerald T Bida; Michael R Zalutsky
A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5).
Nuclear medicine and biology 2012;39(7):1012-8.
2012: Daisuke Asai; Daniel J Callahan; Stephen L Craig; Felipe Garcia Quiroz; Wenge Liu; Donghua Xu; Michael R Zalutsky; Ashutosh Chilkoti
Protein polymer hydrogels by in situ, rapid and reversible self-gelation.
Biomaterials 2012;33(21):5451-8.
2012: Tatiana A Slastnikova; Alexander S Sobolev; Ganesan Vaidyanathan; Eftychia Koumarianou; Tatiana N Lupanova; Andrey A Rosenkranz; Michael R Zalutsky
Modular nanotransporters: a versatile approach for enhancing nuclear delivery and cytotoxicity of Auger electron-emitting 125I.
EJNMMI research 2012;2(1):59.
2012: Tatiana A Slastnikova; Michael R Zalutsky; Pavel V Gulak; Yuri V Khramtsov; Tatiana N Lupanova; Andrey A Rosenkranz; Raymond M Schiffelers; Alexander S Sobolev
Modular nanotransporters: a multipurpose in vivo working platform for targeted drug delivery.
International journal of nanomedicine 2012;7():467-82.
2011: Ganesan Vaidyanathan; Michael R Zalutsky; Linda Grasfeder; Darryl McDougald; Bennett Chin
An alternative and expedient synthesis of radioiodinated 4-iodophenylalanine.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2011;69(10):1401-6.
2011: John H Sampson; Terence Z Wong; Michael R Zalutsky; Daniel P Barboriak; Martin Brady; Allan H Friedman; Denise Lally-Goss; Ankit I Mehta; Neil Petry; Raghu Raghavan; David A Reardon; Darell D Bigner
Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans.
Neurosurgery 2011;69(3):668-76.
2011: Satish K Chitneni; Gregory Palmer; Michael R Zalutsky; Mark W Dewhirst
Molecular imaging of hypoxia.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(2):165-8.
2011: Ganesan Vaidyanathan; Benjamin White; Donna J Affleck; Darryl McDougald; Michael R Zalutsky
Radioiodinated O(6)-Benzylguanine derivatives containing an azido function.
Nuclear medicine and biology 2011;38(1):77-92.
2010: Yukinari Kato; Ganesan Vaidyanathan; Mika Kato Kaneko; Kazuhiko Mishima; Nidhi Srivastava; Vidyalakshmi Chandramohan; Charles N Pegram; Stephen T Keir; Chien-Tsun Kuan; Darell D Bigner; Michael R Zalutsky
Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.
Nuclear medicine and biology 2010;37(7):785-94.
2010: Marc Hens; Ganesan Vaidyanathan; Xiao-Guang Zhao; Darell D Bigner; Michael R Zalutsky
Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Nuclear medicine and biology 2010;37(7):741-50.
2010: Weiping Gao; Wenge Liu; Trine Christensen; Michael R Zalutsky; Ashutosh Chilkoti
In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(38):16432-7.
2010: Chien-Tsun Kuan; Nidhi Srivastava; Roger E McLendon; Wayne A Marasco; Michael R Zalutsky; Darell D Bigner
Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas.
International journal of cancer. Journal international du cancer 2010;127(3):598-611.
2010: Wenge Liu; J Andrew MacKay; Matthew R Dreher; Mingnan Chen; Jonathan R McDaniel; Andrew J Simnick; Daniel J Callahan; Michael R Zalutsky; Ashutosh Chilkoti
Injectable intratumoral depot of thermally responsive polypeptide-radionuclide conjugates delays tumor progression in a mouse model.
Journal of controlled release : official journal of the Controlled Release Society 2010;144(1):2-9.
2009: Chien-Tsun Kuan; Carol J Wikstrand; Roger E McLendon; Michael R Zalutsky; Ujendra Kumar; Darell D Bigner
Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma.
Hybridoma (2005) 2009;28(6):389-403.
2009: Ganesan Vaidyanathan; Haijing Song; Donna J Affleck; Darryl L McDougald; Robert W Storms; Michael R Zalutsky; Bennett B Chin
Targeting aldehyde dehydrogenase: a potential approach for cell labeling.
Nuclear medicine and biology 2009;36(8):919-29.
2009: W Gao; Wenge Liu; John Andrew Mackay; Michael R Zalutsky; Eric J Toone; Ashutosh Chilkoti
In situ growth of a stoichiometric PEG-like conjugate at a protein's N-terminus with significantly improved pharmacokinetics.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(36):15231-6.
2009: Ganesan Vaidyanathan; Emmanuelle Jestin; Tove Olafsen; Anna M Wu; Michael R Zalutsky
Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.
Nuclear medicine and biology 2009;36(6):671-80.
2009: Abraham Boskovitz; Roger E McLendon; Tatsunori Okamura; John H Sampson; Darell D Bigner; Michael R Zalutsky
Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.
Nuclear medicine and biology 2009;36(6):659-69.
2009: Marc Hens; Ganesan Vaidyanathan; Philip Welsh; Michael R Zalutsky
Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.
Nuclear medicine and biology 2009;36(2):117-28.
2008: Andrey A Rosenkranz; Ganesan Vaidyanathan; Oscar R Pozzi; Vladimir G Lunin; Michael R Zalutsky; Alexander S Sobolev
Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At.
International journal of radiation oncology, biology, physics 2008;72(1):193-200.
2008: John H Sampson; Gamal Akabani; Gary E Archer; Mitchel S Berger; R Edward Coleman; Allan H Friedman; Henry S Friedman; Kim Greer; James E Herndon; Sandeep Kunwar; Roger E McLendon; Alison Paolino; Neil Petry; James M Provenzale; David A Reardon; Terence Z Wong; Michael R Zalutsky; Ira Pastan; Darell D Bigner
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.
Neuro-oncology 2008;10(3):320-9.
2008: Marek Pruszyński; Aleksander Bilewicz; Michael R Zalutsky
Preparation of Rh[16aneS4-diol](211)At and Ir[16aneS4-diol](211)At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis.
Bioconjugate chemistry 2008;19(4):958-65.
2008: David A Reardon; Michael R Zalutsky; Gamal Akabani; R Edward Coleman; Allan H Friedman; James E Herndon; Roger E McLendon; Charles N Pegram; Jennifer A Quinn; Jeremy Rich; James J Vredenburgh; Annick Desjardins; Sridharan Guruangan; Susan Boulton; Renee H Raynor; Jeannette M Dowell; Terence Z Wong; Xiao-Guang Zhao; Henry S Friedman; Darell D Bigner
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
Neuro-oncology 2008;10(2):182-9.
2008: Michael R Zalutsky; David A Reardon; Gamal Akabani; R Edward Coleman; Allan H Friedman; Henry S Friedman; Roger E McLendon; Terence Z Wong; Darell D Bigner
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2008;49(1):30-8.
2007: Milos Petrik; Alice Laznickova; Milan Laznicek; Michael R Zalutsky
Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate.
Anticancer research 2007;27(6B):3941-6.
2007: Ganesan Vaidyanathan; Donna J Affleck; Joseph Norman; Susan O'Dorisio; Michael R Zalutsky
A radioiodinated MIBG-octreotate conjugate exhibiting enhanced uptake and retention in SSTR2-expressing tumor cells.
Bioconjugate chemistry 2007;18(6):2122-30.
2007: Michael R Zalutsky; David A Reardon; Oscar R Pozzi; Ganesan Vaidyanathan; Darell D Bigner
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.
Nuclear medicine and biology 2007;34(7):779-85.
2007: Oscar R Pozzi; Michael R Zalutsky
Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 3: alpha-particle-induced radiolytic effects on the chemical behavior of (211)At.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2007;48(7):1190-6.
2007: Ganesan Vaidyanathan; Donna J Affleck; Kevin L Alston; Xiao-Guang Zhao; Marc Hens; Duncan H Hunter; John Babich; Michael R Zalutsky
A kit method for the high level synthesis of [211At]MABG.
Bioorganic & medicinal chemistry 2007;15(10):3430-6.
2007: Roger E McLendon; Gamal Akabani; Henry S Friedman; David A Reardon; Linda Cleveland; Ilkcan Cokgor; James E Herndon; Carol J Wikstrand; Susan T Boulton; Allan H Friedman; Darell D Bigner; Michael R Zalutsky
Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.
Nuclear medicine and biology 2007;34(4):405-13.
2007: David A Reardon; Michael R Zalutsky; Darell D Bigner
Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.
Expert review of anticancer therapy 2007;7(5):675-87.
2007: Alexander T Yordanov; Marc Hens; Charles N Pegram; Darell D Bigner; Michael R Zalutsky
Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Nuclear medicine and biology 2007;34(2):173-83.
2007: Robert J Mairs; Natasha E Fullerton; Michael R Zalutsky; Marie Boyd
Targeted radiotherapy: microgray doses and the bystander effect.
Dose-response : a publication of International Hormesis Society 2007;5(3):204-13.
2007: Ganesan Vaidyanathan; Michael R Zalutsky
Synthesis of N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate: a radio-iodination agent for labeling internalizing proteins and peptides.
Nature protocols 2007;2(2):282-6.
2006: Wenge Liu; Matthew R Dreher; Darin Yale Furgeson; Katia V Peixoto; Hong Yuan; Michael R Zalutsky; Ashutosh Chilkoti
Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice.
Journal of controlled release : official journal of the Controlled Release Society 2006;116(2):170-8.
2006: Helawe Betre; Wenge Liu; Michael R Zalutsky; Ashutosh Chilkoti; Virginia B Kraus; Lori A Setton
A thermally responsive biopolymer for intra-articular drug delivery.
Journal of controlled release : official journal of the Controlled Release Society 2006;115(2):175-82.
2006: Wenge Liu; Matthew R Dreher; Dominic C Chow; Michael R Zalutsky; Ashutosh Chilkoti
Tracking the in vivo fate of recombinant polypeptides by isotopic labeling.
Journal of controlled release : official journal of the Controlled Release Society 2006;114(2):184-92.
2006: Michael R Zalutsky
Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(8):1238-40.
2006: Ganesan Vaidyanathan; Kevin L Alston; Darell D Bigner; Michael R Zalutsky
Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies.
Bioconjugate chemistry 2006;17(4):1085-92.
2006: Marie Boyd; Susan C Ross; Jennifer Dorrens; Natasha E Fullerton; Ker Wei Tan; Michael R Zalutsky; Robert J Mairs
Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(6):1007-15.
2006: David A Reardon; Jennifer A Quinn; Gamal Akabani; R Edward Coleman; Allan H Friedman; Henry S Friedman; James E Herndon; Roger E McLendon; Charles N Pegram; James M Provenzale; Jeannette M Dowell; Jeremy Rich; James J Vredenburgh; Annick Desjardins; John H Sampson; Sridharan Gururangan; Terence Z Wong; Michael A Badruddoja; Xiao-Guang Zhao; Darell D Bigner; Michael R Zalutsky
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(6):912-8.
2006: Sriram Shankar; Michael R Zalutsky; Henry Friedman; Ganesan Vaidyanathan
Molecular imaging of alkylguanine-DNA alkyltransferase: further evaluation of radioiodinated derivatives of O6-benzylguanine.
Nuclear medicine and biology 2006;33(3):399-407.
2006: Gamal Akabani; Sean Denis Carlin; Philip Welsh; Michael R Zalutsky
In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.
Nuclear medicine and biology 2006;33(3):333-47.
2006: Michael R Zalutsky
Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):1958-60.
2006: Ganesan Vaidyanathan; Michael R Zalutsky
Synthesis of N-succinimidyl 4-[18F]fluorobenzoate, an agent for labeling proteins and peptides with 18F.
Nature protocols 2006;1(4):1655-61.
2006: Ganesan Vaidyanathan; Michael R Zalutsky
Preparation of N-succinimidyl 3-[*I]iodobenzoate: an agent for the indirect radioiodination of proteins.
Nature protocols 2006;1(2):707-13.
2006: Sriram Shankar; Ganesan Vaidyanathan; Chien-Tsun Kuan; Darell D Bigner; Michael R Zalutsky
Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
Nuclear medicine and biology 2006;33(1):101-10.
2006: Ganesan Vaidyanathan; Donna J Affleck; Margret Schottelius; Hans-Jürgen Wester; Henry S Friedman; Michael R Zalutsky
Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and 211At via a tin precursor.
Bioconjugate chemistry 2006;17(1):195-203.
2006: David A Reardon; Gamal Akabani; R Edward Coleman; Allan H Friedman; Henry S Friedman; James E Herndon; Roger E McLendon; Charles N Pegram; James M Provenzale; Jennifer A Quinn; Jeremy Rich; James J Vredenburgh; Annick Desjardins; Sridharan Gururangan; Sri Guruangan; Michael A Badruddoja; Jeannette M Dowell; Terence Z Wong; Xiao-Guang Zhao; Michael R Zalutsky; Darell D Bigner
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):115-22.
2005: Natasha E Fullerton; Marie Boyd; Susan C Ross; Sally L Pimlott; John Babich; David Kirk; Michael R Zalutsky; Robert J Mairs
Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
Medicinal chemistry (Shāriqah (United Arab Emirates)) 2005;1(6):611-8.
2005: Oscar R Pozzi; Michael R Zalutsky
Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(8):1393-400.
2005: Sriram Shankar; Michael R Zalutsky; Ganesan Vaidyanathan
O6-3-[125I]iodobenzyl-2'-deoxyguanosine ([125I]IBdG): synthesis and evaluation of its usefulness as an agent for quantification of alkylguanine-DNA alkyltransferase (AGT).
Bioorganic & medicinal chemistry 2005;13(12):3889-98.
2005: Gamal Akabani; David A Reardon; R Edward Coleman; Terence Z Wong; Scott D Metzler; James Bowsher; Daniel P Barboriak; James M Provenzale; Kim L Greer; David DeLong; Henry S Friedman; Allan H Friedman; Xiao-Guang Zhao; Charles N Pegram; Roger E McLendon; Darell D Bigner; Michael R Zalutsky
Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(6):1042-51.
2005: Oscar R Pozzi; Michael R Zalutsky
Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(4):700-6.
2005: Ganesan Vaidyanathan; Donna J Affleck; Michael R Zalutsky
No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2005;62(3):435-40.
2005: Marlene L Hauck; Michael R Zalutsky
Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: Application of the thermal equivalency equation.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2005;21(1):13-27.
2005: Marlene L Hauck; Michael R Zalutsky
Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2005;21(1):1-11.
2005: Michael R Zalutsky
Current status of therapy of solid tumors: brain tumor therapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46 Suppl 1():151S-6S.
2004: Michael R Zalutsky; Oscar R Pozzi
Radioimmunotherapy with alpha-particle emitting radionuclides.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2004;48(4):289-96.
2004: Ganesan Vaidyanathan; Abraham Boskovitz; Sriram Shankar; Michael R Zalutsky
Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers.
Peptides 2004;25(12):2087-97.
2004: Sriram Shankar; Ganesan Vaidyanathan; Donna J Affleck; Katia Peixoto; Darell D Bigner; Michael R Zalutsky
Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.
Nuclear medicine and biology 2004;31(7):909-19.
2004: Ganesan Vaidyanathan; Philip Welsh; Katia C Vitorello; Stacey Snyder; Henry S Friedman; Michael R Zalutsky
A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
European journal of nuclear medicine and molecular imaging 2004;31(10):1362-70.
2004: Abraham Boskovitz; Carol J Wikstrand; Chien-Tsun Kuan; Michael R Zalutsky; David A Reardon; Darell D Bigner
Monoclonal antibodies for brain tumour treatment.
Expert opinion on biological therapy 2004;4(9):1453-71.
2004: Ganesan Vaidyanathan; Donna J Affleck; Kevin L Alston; Philip Welsh; Michael R Zalutsky
Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells.
Nuclear medicine communications 2004;25(9):947-55.
2004: Marie Boyd; Robert J Mairs; Nicol Keith; Susan C Ross; Philip Welsh; Gamal Akabani; Jonathan Owens; Ganesan Vaidyanathan; Ross Carruthers; Jennifer Dorrens; Michael R Zalutsky
An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects.
The journal of gene medicine 2004;6(8):937-47.
2004: David A Rizzieri; Gamal Akabani; Michael R Zalutsky; R Edward Coleman; Scott D Metzler; James Bowsher; Bonnie Toaso; Elizabeth Anderson; Anand S Lagoo; Steve Clayton; Charles N Pegram; Joseph O Moore; Jon P Gockerman; Carlos M DeCastro; Cristina Gasparetto; Nelson J Chao; Darell D Bigner
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.
Blood 2004;104(3):642-8.
2004: Michael R Zalutsky
Targeted radiotherapy of brain tumours.
British journal of cancer 2004;90(8):1469-73.
2004: Ganesan Vaidyanathan; Sriram Shankar; Donna J Affleck; Kevin L Alston; Joseph Norman; Philip Welsh; Holly LeGrand; Michael R Zalutsky
Meta-iodobenzylguanidine derivatives containing a second guanidine moiety.
Bioorganic & medicinal chemistry 2004;12(7):1649-56.
2004: Abraham Boskovitz; Gamal Akabani; Charles N Pegram; Darell D Bigner; Michael R Zalutsky
Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma.
Nuclear medicine and biology 2004;31(3):345-55.
2004: Ganesan Vaidyanathan; Donna J Affleck; Joseph Norman; Philip Welsh; Wenge Liu; Stewart P Johnson; Henry S Friedman; Michael R Zalutsky
O6-3-[131I]iodobenzylguanine: improved synthesis and further evaluation of a potential agent for imaging of alkylguanine-DNA alkyltransferase.
Bioconjugate chemistry 2004;15(2):402-8.
2004: Michael R Zalutsky; Barbara Petelenz
Targeted Radiotherapy with Alpha-Particle Emitting Radionuclides Seminar, November 18, 2004, Cracow, Poland.
Nuclear medicine review. Central & Eastern Europe 2004;7(2):195.
2004: Ganesan Vaidyanathan; Michael R Zalutsky
Imaging drug resistance with radiolabeled molecules.
Current pharmaceutical design 2004;10(24):2965-79.
2004: D Scott Wilbur; Ming-Kuan Chyan; Donald K Hamlin; Brian B Kegley; Reudi Risler; Pradip M Pathare; Janna Quinn; Robert L Vessella; Catherine Foulon; Michael R Zalutsky; Timothy J Wedge; M Frederick Hawthorne
Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds.
Bioconjugate chemistry 2004;15(1):203-23.
2003: Peter M Grossi; Hidenobu Ochiai; Gary E Archer; Roger E McLendon; Michael R Zalutsky; Allan H Friedman; Henry S Friedman; Darell D Bigner; John H Sampson
Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5514-20.
2003: Sean Denis Carlin; Gamal Akabani; Michael R Zalutsky
In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(11):1827-38.
2003: John H Sampson; Gamal Akabani; Gary E Archer; Darell D Bigner; Mitchel S Berger; Allan H Friedman; Henry S Friedman; James E Herndon; Sandeep Kunwar; Steve Marcus; Roger E McLendon; Alison Paolino; Kara Penne; James M Provenzale; Jennifer Quinn; David A Reardon; Jeremy Rich; Timothy T Stenzel; Sandra Tourt-Uhlig; Carol J Wikstrand; Terence Wong; Roger Williams; Fan Yuan; Michael R Zalutsky; Ira Pastan
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.
Journal of neuro-oncology 2003;65(1):27-35.
2003: Ganesan Vaidyanathan; Donna J Affleck; Darell D Bigner; Michael R Zalutsky
N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At.
Nuclear medicine and biology 2003;30(4):351-9.
2003: Ganesan Vaidyanathan; Henry S Friedman; Donna J Affleck; Margret Schottelius; Hans-Jürgen Wester; Michael R Zalutsky
Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(5):1868-76.
2003: Gamal Akabani; Stephen J Kennel; Michael R Zalutsky
Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(5):792-805.
2003: Sriram Shankar; Ganesan Vaidyanathan; Donna J Affleck; Philip Welsh; Michael R Zalutsky
N-succinimidyl 3-[(131)I]iodo-4-phosphonomethylbenzoate ([(131)I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs.
Bioconjugate chemistry 2003;14(2):331-41.
2002: Gamal Akabani; Roger E McLendon; Darell D Bigner; Michael R Zalutsky
Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis.
International journal of radiation oncology, biology, physics 2002;54(4):1259-75.
2002: Sean Denis Carlin; Robert J Mairs; Philip Welsh; Michael R Zalutsky
Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells.
Nuclear medicine and biology 2002;29(7):729-39.
2002: Clifford R Berry; Timothy R DeGrado; Felicia B Nutter; Pradeep K Garg; Edward B Breitschwerdt; Kathy A Spaulding; Kevin D Concannon; Michael R Zalutsky; R Edward Coleman
Imaging of pheochromocytoma in 2 dogs using p-[18F] fluorobenzylguanidine.
Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association 2002;43(2):183-6.
2002: David A Reardon; Gamal Akabani; R Edward Coleman; Allan H Friedman; Henry S Friedman; James E Herndon; Ilkcan Cokgor; Roger E McLendon; Charles N Pegram; James M Provenzale; Jennifer A Quinn; Jeremy Rich; Lorna V Regalado; John H Sampson; Timothy D Shafman; Carol J Wikstrand; Terence Z Wong; Xiao-Guang Zhao; Michael R Zalutsky; Darell D Bigner
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1389-97.
2002: Ganesan Vaidyanathan; Donna J Affleck; Darell D Bigner; Michael R Zalutsky
Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate.
Nuclear medicine and biology 2002;29(1):1-11.
2001: Michael R Zalutsky; Xiao-Guang Zhao; Kevin L Alston; Darell D Bigner
High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2001;42(10):1508-15.
2001: CF Foulon; Philip Welsh; Darell D Bigner; Michael R Zalutsky
Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR.
Nuclear medicine and biology 2001;28(7):769-77.
2001: Ganesan Vaidyanathan; Sriram Shankar; Donna J Affleck; Philip Welsh; SK Slade; Michael R Zalutsky
Biological evaluation of ring- and side-chain-substituted m-iodobenzylguanidine analogues.
Bioconjugate chemistry 2001;12(5):798-806.
2001: Ganesan Vaidyanathan; Sriram Shankar; Michael R Zalutsky
Synthesis of ring- and side-chain-substituted m-iodobenzylguanidine analogues.
Bioconjugate chemistry 2001;12(5):786-97.
2001: Ganesan Vaidyanathan; Donna J Affleck; J Li; Philip Welsh; Michael R Zalutsky
A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB).
Bioconjugate chemistry 2001;12(3):428-38.
2001: Ilkcan Cokgor; Gamal Akabani; Henry S Friedman; Allan H Friedman; Michael R Zalutsky; L M Zehngebot; James M Provenzale; CD Guy; Carol J Wikstrand; Darell D Bigner
Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study.
Cancer 2001;91(9):1809-13.
2001: Dan E Meyer; GA Kong; Mark Dewhirst; Michael R Zalutsky; Ashutosh Chilkoti
Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia.
Cancer research 2001;61(4):1548-54.
2000: Chien-Tsun Kuan; Carol J Wikstrand; Gary E Archer; R Beers; Ira Pastan; Michael R Zalutsky; Darell D Bigner
Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv.
International journal of cancer. Journal international du cancer 2000;88(6):962-9.
2000: Ilkcan Cokgor; Gamal Akabani; Chien-Tsun Kuan; Henry S Friedman; Allan H Friedman; R Edward Coleman; Roger E McLendon; Sandra H Bigner; Xiao-Guang Zhao; AM Garcia-Turner; Charles N Pegram; Carol J Wikstrand; Timothy D Shafman; James E Herndon; James M Provenzale; Michael R Zalutsky; Darell D Bigner
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(22):3862-72.
2000: Ganesan Vaidyanathan; Donna J Affleck; C M Cavazos; Stewart P Johnson; Sriram Shankar; Henry S Friedman; M O Colvin; Michael R Zalutsky
Radiolabeled guanine derivatives for the in vivo mapping of O(6)-alkylguanine-DNA alkyltransferase: 6-(4-[(18)F]Fluoro-benzyloxy)-9H-purin-2-ylamine and 6-(3-[(131)I]Iodo-benzyloxy)-9H-purin-2-ylamine.
Bioconjugate chemistry 2000;11(6):868-75.
2000: Michael R Zalutsky; Ganesan Vaidyanathan
Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy.
Current pharmaceutical design 2000;6(14):1433-55.
2000: CF Foulon; Craig J Reist; Darell D Bigner; Michael R Zalutsky
Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
Cancer research 2000;60(16):4453-60.
2000: F Xu; Steven A Leadon; Yinhua Yu; CM Boyer; KC O'Briant; K Ward; Amanda McWatters; X Zhao; D S Bae; Karen DeSombre; Michael R Zalutsky; Robert C Bast
Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):3334-41.
2000: Ganesan Vaidyanathan; Donna J Affleck; Philip Welsh; A Srinivasan; M Schmidt; Michael R Zalutsky
Radioiodination and astatination of octreotide by conjugation labeling.
Nuclear medicine and biology 2000;27(4):329-37.
2000: Gamal Akabani; Ilkcan Cokgor; R Edward Coleman; D González Trotter; Terence Z Wong; Henry S Friedman; Allan H Friedman; AM Garcia-Turner; James E Herndon; David DeLong; Roger E McLendon; Xiao-Guang Zhao; Charles N Pegram; James M Provenzale; Darell D Bigner; Michael R Zalutsky
Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.
International journal of radiation oncology, biology, physics 2000;46(4):947-58.
1999: Michael R Zalutsky; FJ Xu; Y Yu; CF Foulon; Xiao-Guang Zhao; SK Slade; Donna J Affleck; Robert C Bast
Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution.
Nuclear medicine and biology 1999;26(7):781-90.
1999: CF Foulon; Darell D Bigner; Michael R Zalutsky
Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications.
Bioconjugate chemistry 1999;10(5):867-76.
1999: Roger E McLendon; Gary E Archer; Roy H Larsen; Gamal Akabani; Darell D Bigner; Michael R Zalutsky
Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis.
International journal of radiation oncology, biology, physics 1999;45(2):491-9.
1999: Chien-Tsun Kuan; Craig J Reist; CF Foulon; I A Lorimer; Gary E Archer; Charles N Pegram; Ira Pastan; Michael R Zalutsky; Darell D Bigner
125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(6):1539-49.
1999: Craig J Reist; CF Foulon; Kevin L Alston; Darell D Bigner; Michael R Zalutsky
Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.
Nuclear medicine and biology 1999;26(4):405-11.
1999: Gamal Akabani; Craig J Reist; Ilkcan Cokgor; Allan H Friedman; Henry S Friedman; R Edward Coleman; Xiao-Guang Zhao; Darell D Bigner; Michael R Zalutsky
Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(4):631-8.
1998: Ganesan Vaidyanathan; Michael R Zalutsky; Timothy R DeGrado
Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguanidine.
Bioconjugate chemistry 1998;9(6):758-64.
1998: Craig J Reist; Darell D Bigner; Michael R Zalutsky
Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(10):2495-502.
1998: Marlene L Hauck; Michael R Zalutsky
The effects of local hyperthermia on the catabolism of a radioiodinated chimeric monoclonal antibody.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(9):2071-7.
1998: Ganesan Vaidyanathan; Michael R Zalutsky
Preparation of 5-[131I]iodo- and 5-[211At]astato-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil by a halodestannylation reaction.
Nuclear medicine and biology 1998;25(5):487-96.
1998: SH Cunningham; Robert J Mairs; TE Wheldon; Philip Welsh; Ganesan Vaidyanathan; Michael R Zalutsky
Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.
British journal of cancer 1998;77(12):2061-8.
1998: Darell D Bigner; M T Brown; Allan H Friedman; R Edward Coleman; Gamal Akabani; Henry S Friedman; W L Thorstad; Roger E McLendon; Sandra H Bigner; Xiao-Guang Zhao; Charles N Pegram; Carol J Wikstrand; James E Herndon; N A Vick; Nina Paleologos; Ilkcan Cokgor; James M Provenzale; Michael R Zalutsky
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(6):2202-12.
1998: Roy H Larsen; SK Slade; Michael R Zalutsky
Blocking [211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds.
Nuclear medicine and biology 1998;25(4):351-7.
1998: Carol J Wikstrand; Craig J Reist; Gary E Archer; Michael R Zalutsky; Darell D Bigner
The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.
Journal of neurovirology 1998;4(2):148-58.
1998: Marlene L Hauck; Roy H Larsen; Philip Welsh; Michael R Zalutsky
Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia.
British journal of cancer 1998;77(5):753-9.
1998: CF Foulon; Kevin L Alston; Michael R Zalutsky
Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy.
Nuclear medicine and biology 1998;25(2):81-8.
1998: Roy H Larsen; Gamal Akabani; Philip Welsh; Michael R Zalutsky
The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.
Radiation research 1998;149(2):155-62.
1998: Timothy R DeGrado; Michael R Zalutsky; R Edward Coleman; Ganesan Vaidyanathan
Effects of specific activity on meta-[(131)I]iodobenzylguanidine kinetics in isolated rat heart.
Nuclear medicine and biology 1998;25(1):59-64.
1997: Gamal Akabani; Michael R Zalutsky
Microdosimetry of astatine-211 using histological images: application to bone marrow.
Radiation research 1997;148(6):599-607.
1997: Craig J Reist; Surinder Batra; Charles N Pegram; Darell D Bigner; Michael R Zalutsky
In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent.
Nuclear medicine and biology 1997;24(7):639-47.
1997: Ganesan Vaidyanathan; Donna J Affleck; Michael R Zalutsky
Method for radioiodination of proteins using N-succinimidyl 3-hydroxy-4-iodobenzoate.
Bioconjugate chemistry 1997;8(5):724-9.
1997: FJ Xu; YH Yu; D S Bae; Xiao-Guang Zhao; SK Slade; CM Boyer; Robert C Bast; Michael R Zalutsky
Radioiodinated antibody targeting of the HER-2/neu oncoprotein.
Nuclear medicine and biology 1997;24(5):451-9.
1997: Roy H Larsen; Ganesan Vaidyanathan; Michael R Zalutsky
Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells.
International journal of radiation biology 1997;72(1):79-90.
1997: Marlene L Hauck; D O Coffin; R K Dodge; Mark Dewhirst; J B Mitchell; Michael R Zalutsky
A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 1997;13(3):307-16.
1997: Craig J Reist; Gary E Archer; Carol J Wikstrand; Darell D Bigner; Michael R Zalutsky
Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
Cancer research 1997;57(8):1510-5.
1997: Michael R Zalutsky; M G Stabin; Roy H Larsen; Darell D Bigner
Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate.
Nuclear medicine and biology 1997;24(3):255-61.
1997: CF Foulon; Kevin L Alston; Michael R Zalutsky
Synthesis and preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide and ((5-iodo-3-pyridinyl)carbonyl)norbiotinamide: two radioiodinated biotin conjugates with improved stability.
Bioconjugate chemistry 1997;8(2):179-86.
1997: Ganesan Vaidyanathan; Michael R Zalutsky
Fluorine-18-labeled [Nle4,D-Phe7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue.
Nuclear medicine and biology 1997;24(2):171-8.
1997: CF Foulon; B W Schoultz; Michael R Zalutsky
Preparation and biological evaluation of an astatine-211 labeled biotin conjugate: biotinyl-3-[211 At]astatoanilide.
Nuclear medicine and biology 1997;24(2):135-43.
1997: Ganesan Vaidyanathan; Xiao-Guang Zhao; Dudley K Strickland; Michael R Zalutsky
No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1997;38(2):330-4.
1997: Marlene L Hauck; Mark Dewhirst; Darell D Bigner; Michael R Zalutsky
Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(1):63-70.
1997: Ganesan Vaidyanathan; Xiao-Guang Zhao; Roy H Larsen; Michael R Zalutsky
3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
British journal of cancer 1997;76(2):226-33.
1996: Craig J Reist; Pradeep K Garg; Kevin L Alston; Darell D Bigner; Michael R Zalutsky
Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
Cancer research 1996;56(21):4970-7.
1996: Ganesan Vaidyanathan; Michael R Zalutsky
Targeted therapy using alpha emitters.
Physics in medicine and biology 1996;41(10):1915-31.
1996: Ganesan Vaidyanathan; Henry S Friedman; Stephen T Keir; Michael R Zalutsky
Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model.
Nuclear medicine and biology 1996;23(6):851-6.
1996: M T Brown; R Edward Coleman; Allan H Friedman; Henry S Friedman; Roger E McLendon; R Reiman; G J Felsberg; RD Tien; Sandra H Bigner; Michael R Zalutsky; Xiao-Guang Zhao; Carol J Wikstrand; Charles N Pegram; J E Herndon; N A Vick; Nina Paleologos; R K Fredericks; S Clifford Schold; Darell D Bigner
Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(6):963-72.
1996: M L Hauck; Mark Dewhirst; Michael R Zalutsky
The effects of clinically relevant hyperthermic temperatures on the kinetic binding parameters of a monoclonal antibody.
Nuclear medicine and biology 1996;23(4):551-7.
1996: Michael R Zalutsky; Gary E Archer; Pradeep K Garg; Surinder Batra; Darell D Bigner
Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent.
Nuclear medicine and biology 1996;23(4):449-58.
1996: Ganesan Vaidyanathan; Henry S Friedman; Stephen T Keir; Michael R Zalutsky
Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity.
British journal of cancer 1996;73(10):1171-7.
1996: Roger E McLendon; Gary E Archer; Pradeep K Garg; Darell D Bigner; Michael R Zalutsky
Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis.
International journal of radiation oncology, biology, physics 1996;35(1):69-80.
1996: Ganesan Vaidyanathan; Roy H Larsen; Michael R Zalutsky
5-[211 At]astato-2'-deoxyuridine, an alpha particle-emitting endoradiotherapeutic agent undergoing DNA incorporation.
Cancer research 1996;56(6):1204-9.
1996: Pradeep K Garg; Kevin L Alston; P C Welsh; Michael R Zalutsky
Enhanced binding and inertness to dehalogenation of alpha-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate.
Bioconjugate chemistry 1996;7(2):233-9.
1996: Roy H Larsen; B W Wieland; Michael R Zalutsky
Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (alpha,2n)211 at reaction.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 1996;47(2):135-43.
1996: Ganesan Vaidyanathan; Donna J Affleck; Michael R Zalutsky
No-carrier-added (4-fluoro-3-[131I]iodobenzyl)guanidine and (3-[211At]astato-4-fluorobenzyl)guanidine.
Bioconjugate chemistry 1996;7(1):102-7.
1996: Michael R Zalutsky; J M Schuster; Pradeep K Garg; Gary E Archer; Mark Dewhirst; Darell D Bigner
Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1996;141():101-22.
1996: Michael R Zalutsky; Darell D Bigner
Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.
Acta oncologica (Stockholm, Sweden) 1996;35(3):373-9.
1996: T Olafsen; Oyvind S Bruland; Michael R Zalutsky; Inger Sandlie
Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Application to radiolabeling.
Acta oncologica (Stockholm, Sweden) 1996;35(3):297-301.
1995: Craig J Reist; Gary E Archer; S N Kurpad; Carol J Wikstrand; Ganesan Vaidyanathan; M C Willingham; Moscatello David; Albert J Wong; Darell D Bigner; Michael R Zalutsky
Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.
Cancer research 1995;55(19):4375-82.
1995: T Olafsen; Oyvind S Bruland; Michael R Zalutsky; Inger Sandlie
Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: location of lysine residues and implications for radiolabeling.
Nuclear medicine and biology 1995;22(6):765-71.
1995: Ganesan Vaidyanathan; Michael R Zalutsky
Fluorine-18 labeled chemotactic peptides: a potential approach for the PET imaging of bacterial infection.
Nuclear medicine and biology 1995;22(6):759-64.
1995: Pradeep K Garg; Kevin L Alston; Michael R Zalutsky
Catabolism of radioiodinated murine monoclonal antibody F(ab')2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods.
Bioconjugate chemistry 1995;6(4):493-501.
1995: Pradeep K Garg; C S John; Michael R Zalutsky
Preparation and preliminary evaluation of 4-[211At]astato-N-piperidinoethyl benzamide.
Nuclear medicine and biology 1995;22(4):467-73.
1995: Ganesan Vaidyanathan; Donna J Affleck; Michael R Zalutsky
Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1995;36(4):644-50.
1995: Dudley K Strickland; Ganesan Vaidyanathan; Henry S Friedman; Michael R Zalutsky
Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.
Journal of neuro-oncology 1995;25(1):9-17.
1995: Ganesan Vaidyanathan; Michael R Zalutsky
No-carrier-added meta-[123I]iodobenzylguanidine: synthesis and preliminary evaluation.
Nuclear medicine and biology 1995;22(1):61-4.
1995: E L Johnson; Timothy G Turkington; Ronald J Jaszczak; David Gilland; Ganesan Vaidyanathan; Kim L Greer; R Edward Coleman; Michael R Zalutsky
Quantitation of 211At in small volumes for evaluation of targeted radiotherapy in animal models.
Nuclear medicine and biology 1995;22(1):45-54.
1995: Timothy R DeGrado; Michael R Zalutsky; Ganesan Vaidyanathan
Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart.
Nuclear medicine and biology 1995;22(1):1-12.
1995: J M Schuster; Michael R Zalutsky; M A Noska; R Dodge; Henry S Friedman; Darell D Bigner; Mark Dewhirst
Hyperthermic modulation of radiolabelled antibody uptake in a human glioma xenograft and normal tissues.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 1995;11(1):59-72.
1994: Dudley K Strickland; Ganesan Vaidyanathan; Michael R Zalutsky
Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells.
Cancer research 1994;54(20):5414-9.
1994: Ganesan Vaidyanathan; Donna J Affleck; Michael R Zalutsky
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
Journal of medicinal chemistry 1994;37(21):3655-62.
1994: Michael R Zalutsky; Roger E McLendon; Pradeep K Garg; Gary E Archer; J M Schuster; Darell D Bigner
Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.
Cancer research 1994;54(17):4719-25.
1994: Ganesan Vaidyanathan; Michael R Zalutsky
Improved synthesis of N-succinimidyl 4-[18F]fluorobenzoate and its application to the labeling of a monoclonal antibody fragment.
Bioconjugate chemistry 1994;5(4):352-6.
1994: X He; Gary E Archer; Carol J Wikstrand; S L Morrison; Michael R Zalutsky; Darell D Bigner; Surinder Batra
Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin.
Journal of neuroimmunology 1994;52(2):127-37.
1994: Ganesan Vaidyanathan; Dudley K Strickland; Michael R Zalutsky
Meta-[211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent.
International journal of cancer. Journal international du cancer 1994;57(6):908-13.
1994: Surinder Batra; M L Niswonger; Carol J Wikstrand; Charles N Pegram; Michael R Zalutsky; S L Morrison; Darell D Bigner
Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization.
Hybridoma 1994;13(2):87-97.
1994: Ronald J Jaszczak; J Li; H Wang; Michael R Zalutsky; R Edward Coleman
Pinhole collimation for ultra-high-resolution, small-field-of-view SPECT.
Physics in medicine and biology 1994;39(3):425-37.
1994: Ganesan Vaidyanathan; Donna J Affleck; Michael R Zalutsky
Monoclonal antibody F(ab')2 fragment labeled with N-succinimidyl 2,4-dimethoxy-3-halobenzoates: in vivo comparison of iodinated and astatinated fragments.
Nuclear medicine and biology 1994;21(1):105-10.
1994: Pradeep K Garg; S Garg; Michael R Zalutsky
Synthesis and preliminary evaluation of para- and meta-[18F]fluorobenzylguanidine.
Nuclear medicine and biology 1994;21(1):97-103.
1993: S Garg; Pradeep K Garg; Xiao-Guang Zhao; Henry S Friedman; Darell D Bigner; Michael R Zalutsky
Radioiodination of a monoclonal antibody using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
Nuclear medicine and biology 1993;20(7):835-42.
1993: Timothy G Turkington; Michael R Zalutsky; Ronald J Jaszczak; Pradeep K Garg; Ganesan Vaidyanathan; R Edward Coleman
Measuring astatine-211 distributions with SPECT.
Physics in medicine and biology 1993;38(8):1121-30.
1993: S Clifford Schold; Michael R Zalutsky; R Edward Coleman; M J Glantz; Allan H Friedman; Ronald J Jaszczak; Sandra H Bigner; Darell D Bigner
Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma.
Investigative radiology 1993;28(6):488-96.
1993: Pradeep K Garg; S Garg; Michael R Zalutsky
N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate: synthesis and potential utility for the radioiodination of monoclonal antibodies.
Nuclear medicine and biology 1993;20(4):379-87.
1993: Ganesan Vaidyanathan; Michael R Zalutsky
No-carrier-added synthesis of meta-[131I]iodobenzylguanidine.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 1993;44(3):621-8.
1993: Ganesan Vaidyanathan; Donna J Affleck; Michael R Zalutsky
Radioiodination of proteins using N-succinimidyl 4-hydroxy-3-iodobenzoate.
Bioconjugate chemistry 1993;4(1):78-84.
1992: Ganesan Vaidyanathan; Michael R Zalutsky
1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation.
Bioconjugate chemistry 1992;3(6):499-503.
1992: Pradeep K Garg; S Garg; Darell D Bigner; Michael R Zalutsky
Localization of fluorine-18-labeled Mel-14 monoclonal antibody F(ab')2 fragment in a subcutaneous xenograft model.
Cancer research 1992;52(18):5054-60.
1992: R P Moseley; V Papanastassiou; Michael R Zalutsky; R D Ashpole; S Evans; Darell D Bigner; JT Kemshead
Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates.
International journal of cancer. Journal international du cancer 1992;52(1):38-43.
1992: Ganesan Vaidyanathan; Darell D Bigner; Michael R Zalutsky
Fluorine-18-labeled monoclonal antibody fragments: a potential approach for combining radioimmunoscintigraphy and positron emission tomography.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1992;33(8):1535-41.
1992: Ganesan Vaidyanathan; Michael R Zalutsky
Labeling proteins with fluorine-18 using N-succinimidyl 4-[18F]fluorobenzoate.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1992;19(3):275-81.
1992: Michael R Zalutsky; Pradeep K Garg; S H Johnson; H Utsunomiya; R Edward Coleman
Fluorine-18-antimyosin monoclonal antibody fragments: preliminary investigations in a canine myocardial infarct model.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1992;33(4):575-80.
1992: Pradeep K Garg; S Garg; W G Degraff; Michael R Zalutsky; J B Mitchell
4-Fluorobenzylamine and phenylalanine methyl ester conjugates of 2-nitroimidazole: evaluation as hypoxic cell radiosensitizers.
International journal of radiation oncology, biology, physics 1992;22(3):593-6.
1991: J M Schuster; Pradeep K Garg; Darell D Bigner; Michael R Zalutsky
Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate.
Cancer research 1991;51(16):4164-9.
1991: S Garg; Pradeep K Garg; Michael R Zalutsky
N-succinimidyl 5-(trialkylstannyl)-3-pyridinecarboxylates: a new class of reagents for protein radioiodination.
Bioconjugate chemistry 1991;2(1):50-6.
1991: Pradeep K Garg; S Garg; Michael R Zalutsky
Fluorine-18 labeling of monoclonal antibodies and fragments with preservation of immunoreactivity.
Bioconjugate chemistry 1991;2(1):44-9.
1990: A J Worlock; Michael R Zalutsky; R S Metzgar
Radiolocalization of human pancreatic tumors in athymic mice by monoclonal antibody DU-PAN 1.
Cancer research 1990;50(22):7246-51.
1990: Ganesan Vaidyanathan; Michael R Zalutsky
Radioiodination of antibodies via N-succinimidyl 2,4-dimethoxy-3-(trialkylstannyl)benzoates.
Bioconjugate chemistry 1990;1(6):387-93.
1990: R P Moseley; A G Davies; Richard Richardson; Michael R Zalutsky; S Carrell; J Fabre; N Slack; J Bullimore; B Pizer; V Papanastassiou
Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.
British journal of cancer 1990;62(4):637-42.
1990: Michael R Zalutsky; R P Moseley; J C Benjamin; E V Colapinto; G N Fuller; H P Coakham; Darell D Bigner
Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration.
Cancer research 1990;50(13):4105-10.
1990: Ganesan Vaidyanathan; Michael R Zalutsky
Protein radiohalogenation: observations on the design of N-succinimidyl ester acylation agents.
Bioconjugate chemistry 1990;1(4):269-73.
1990: Pradeep K Garg; C L Harrison; Michael R Zalutsky
Comparative tissue distribution in mice of the alpha-emitter 211At and 131I as labels of a monoclonal antibody and F(ab')2 fragment.
Cancer research 1990;50(12):3514-20.
1990: P A Humphrey; Albert J Wong; Bert Vogelstein; Michael R Zalutsky; G N Fuller; Gary E Archer; Henry S Friedman; Madan M Kwatra; S H Bigner; Darell D Bigner
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(11):4207-11.
1990: E V Colapinto; Michael R Zalutsky; Gary E Archer; M A Noska; Henry S Friedman; S Carrel; Darell D Bigner
Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14.
Cancer research 1990;50(6):1822-7.
1990: D A Cope; Mark Dewhirst; Henry S Friedman; Darell D Bigner; Michael R Zalutsky
Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia.
Cancer research 1990;50(6):1803-9.
1990: Michael R Zalutsky; Pradeep K Garg; A S Narula
Labeling monoclonal antibodies with halogen nuclides.
Acta radiologica. Supplementum 1990;374():141-5.
1989: Michael R Zalutsky; M A Noska; E V Colapinto; Pradeep K Garg; Darell D Bigner
Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate.
Cancer research 1989;49(20):5543-9.
1989: Michael R Zalutsky; Pradeep K Garg; Henry S Friedman; Darell D Bigner
Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(18):7149-53.
1989: Michael R Zalutsky; R P Moseley; H B Coakham; R Edward Coleman; Darell D Bigner
Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.
Cancer research 1989;49(10):2807-13.
1989: Michael R Zalutsky; Robert C Bast; R C Knapp
Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1989;16(4):405-11.
1989: Pradeep K Garg; SK Slade; C L Harrison; Michael R Zalutsky
Labeling proteins using aryl iodide acylation agents: influence of meta vs para substitution on in vivo stability.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1989;16(7):669-73.
1989: Pradeep K Garg; Gary E Archer; Darell D Bigner; Michael R Zalutsky
Synthesis of radioiodinated N-succinimidyl iodobenzoate: optimization for use in antibody labelling.
International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes 1989;40(6):485-90.
1988: E V Colapinto; P A Humphrey; Michael R Zalutsky; D R Groothuis; Henry S Friedman; N de Tribolet; S Carrel; Darell D Bigner
Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts.
Cancer research 1988;48(20):5701-7.
1988: Y Lee; D E Bullard; P A Humphrey; E V Colapinto; Henry S Friedman; Michael R Zalutsky; R Edward Coleman; Darell D Bigner
Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.
Cancer research 1988;48(10):2904-10.
1988: Michael R Zalutsky; A S Narula
Radiohalogenation of a monoclonal antibody using an N-succinimidyl 3-(tri-n-butylstannyl)benzoate intermediate.
Cancer research 1988;48(6):1446-50.
1988: Y S Lee; D E Bullard; Michael R Zalutsky; R Edward Coleman; Carol J Wikstrand; Henry S Friedman; E V Colapinto; Darell D Bigner
Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model.
Cancer research 1988;48(3):559-66.
1988: E V Colapinto; Y S Lee; P A Humphrey; Michael R Zalutsky; Henry S Friedman; D E Bullard; Darell D Bigner
The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice.
British journal of neurosurgery 1988;2(2):179-91.
1988: Michael R Zalutsky; R C Knapp; Robert C Bast
Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1988;15(4):431-7.
1988: Michael R Zalutsky; A S Narula
Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate.
International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes 1988;39(3):227-32.
1987: Michael R Zalutsky; A S Narula
A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine.
International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes 1987;38(12):1051-5.